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Abstract
Cancer of the parotid gland is relatively rare, but carries poor prognosis owing to its prevailing distant metastases.
In addition to the disease’s basic epidemiology and pathology, we review some current discoveries of its
tumorigenesis molecular mechanism. Based on published salivary gland cancer clinical trial data, non-surgical
antitumor efficacies amongst a range of chemotherapy, radiation, and concurrent therapy regimens are compared.
We also present the current development status of novel radiation therapy and targeted therapeutics, focusing on
intensity-modulated radiation therapy (IMRT), and epidermal growth factor receptor (EGFR) and vascular endothelial
growth factor (VEGF) blockages, which are showing promise for improving parotid gland cancer management.
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Anatomy
The salivary glands are important organs in organisms
since they serve as exocrine glands in the secretion of
saliva and the enzyme amylase into the oral cavity to
facilitate mastication and swallowing. There are three
pairs of major salivary glands: the sublingual glands that
are located beneath the tongue, the submandibular
glands that are located below the lower jaw, and the
parotid glands that are located in front of the ears and
extend to the area beneath the earlobe along the lower
border of the jawbone. The parotid glands are the
body’sl a r g e s ts a l i v a r yg l a n d s( S e eF i g u r e1 )[ 1 ] .T h e
minor salivary glands are small glands that number in
the hundreds are located in the lips, bucked mucosa,
and throat linings.
Epidemiology
Compared to other cancers, salivary gland malignancies
are relatively rare in the United States. In 2008, they
comprised only about 12% of oral & pharyngeal cancers
or 0 · 3% of cancers at all sites combined [2]. More
cases have also been noticed in areas of higher ultravio-
let radiation [3]. During the 2000-2008 period, salivary
gland malignancies occurred more often in men at an
average annual incidence rate of 1 · 41 cases per
100,000 males than in women at 1 · 00 [4]. Through the
past few years, its incidence has also slowly increased
among men at about 1 · 2% per year [2]. Although it is
possible for salivary gland cancer to occur in people of
all ages, 2 out of 3 cancers are found in people 55 and
older. On average, people are diagnosed at age of 64 [5].
Most salivary gland tumors are benign. The most com-
m o nb e n i g nt u m o r sa r em i x e dt u m o ra n dW a r t h i n ’s
tumor (See Figure 2a-b).
Salivary gland tumors account for about 5% of all neo-
plasms of the head and neck. Most (75%) occur in the
parotid glands, which are the largest among the three
sets of major salivary glands, 10% arise in the subman-
dibular glands, and 15% are located in minor salivary
glands of the upper digestive tract, less than 1% present
in the sublingual glands [6]. Only about 20% of parotid
gland tumors are malignant. Half of submandibular and
sublingual tumors, and 20% of the minor salivary gland
tumors are benign [7]. The five-year relative survival
rate for salivary gland cancer depends on the stage the
cancer. From Stage I to IV, the rates are 96%, 77%, 73%,
and 37%, respectively [8].
Etiology
Partly owning to the rarity of parotid gland cancer, its
etiology has not been thoroughly studied and the factors
responsible for its carcinogenesis are unclear. Exposures
to tobacco smoke and alcohol intake have not been
found consistently associated with its development.
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exposure to ionizing radiation, as supported by studies
on atomic bomb survivors [9]. Linear dose-dependent
relationships have also been observed [10]. Medical
radiation or ultraviolet light therapeutic treatments to
the head or neck and exposures to full-mouth dental X-
rays have also been linked to an increased risk [11]. The
effect of UV therapeutic light seems to be more evident
in fair-skinned persons, who are naturally more sensitive
to the effects of UV light [12]. Additionally, nitroso
compounds have induced parotid gland tumors in
laboratory mice. The presence of nitroso compounds in
Figure 1 Ilustration of a facial dissection with major salivary glands identified [1].
Figure 2 Salivary gland benign tumor pathology (200 ×).
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gland cancer in rubber industrial workers [13].
Classification
Mucoepidermoid carcinoma is most common cancer in
the parotid gland. Approximately 50% of submandibular
gland cancers are adenoid cystic carcinomas. Minor sali-
vary gland cancers are most often adenoid cystic carci-
nomas and adenocarcinomas, not otherwise classified
[14]. Table 1 shows the histologic types of salivary gland
cancer in order of frequency [15].
The origin of parotid and other salivary gland cancers
is still debated. Possibly, they are derived from both
epithelial and mesenchymal elements, which may
explain their variable patterns (See Figure 3a-d).
Most parotid gland cancers are slow-growing and trea-
table if found in the early stage. Prognosis varies accord-
ing to histologic type and stage. A combination of
radiation therapy and surgery is usually applied to treat
this malignant tumor. Fatalities are usually not a direct
result from the tumor, but typically occur due to metas-
tasis to other organs, especially the lungs.
Tumorigenesis Mechanism
The mechanism behind the development of parotid
gland cancer is not fully understood. One theory
involves vacuolar protein sorting-associated protein 4B
homolog (VPS4B) [16]. This protein is responsible for
vesicular trafficking and the maturation of autophago-
somes in mammalian cells.
In humans, the epidermal growth factor receptor
(EGFR) is a cell-surface receptor that is activated by
binding of its specific ligands, including members of the
epidermal growth factor (EGF) family of extracellular
protein ligands [17,18]. Upon activation, EGFR trans-
forms from an inactive monomeric form to an active
homo/hetero-dimer. The dimerization stimulates its
intrinsic intracellular protein-tyrosine kinase activity and
results in auto-phosphorylation of several tyrosine resi-
dues in its C-terminal domain. This auto-phosphoryla-
tion elicits downstream activation and signaling to other
proteins, which subsequently initiate several signal
transduction cascades governing cell migration,
adhesion, proliferation, differentiation, and death [19].
Controls of the intensity and duration of EGFR signal-
ing are through a negative feedback regulatory mechan-
ism of the EGF-induced EGFR downregulation process
in which activated EGFR is endocytosed and then differ-
entially destined for lysosomal degradation or recycling
via the multi-vesicular bodies (MVBs) [20]. It is during
this endocytic process that vacuolar protein sorting
(VPS) associated-proteins play their role in EGFR regu-
lation. In the formation of intracellular vesicles that bud
into the MVBs, proteins are sorted into membrane
micro domains, the membrane is distorted away from
the cytoplasm, and the vesicle is released via membrane
fission. MVB vesicle formation utilizes the cellular
machinery of Class E VPS proteins [16]. There are 27
different human Class E proteins so far identified. Most
of them function as subunits of the hetero-oligomeric
endosomal sorting complexes required for transport
(ESCRT) complexes, which are sequentially recruited to
sites of vesicle formation. The major EGFR inactivation
pathway of endocytosis utilizes four ESCRTs to culmi-
nate in lysosomal degradation of activated EGFR [21].
During endocytic process, VPS4, an ATPase associated
with various cellular activities (AAA)-ATPase protein
complex [22], is involved in the disassembly of the
ESCRT-III complex, which is required for recycling of
membrane-associated proteins in mammalian cells [23].
Two VPS4 isoforms, VPS4A and VPS4B, can hetero-oIi-
gomerize with each other in mammalian cells. Endocytic
pathway also converges with autophagic pathway, which
is evolutionarily conserved and responsible for seques-
tering targeted proteins and organelles and their subse-
quent degradation in a lysosome-dependent manner
[24]. While a special form of MVBs mediates the trans-
port of cargo to lysosomes, recent studies demonstrated
that the multisubunit complex, ESCRT-III, is required
for autophagosomes to fuse with MVBs and for fusion
of autophagosomes with lysosomes during autophagic
process [25].
Given the essential role for VPS4B in MVB matura-
t i o n ,i ti ss p e c u l a t e dt h a tl oss of VPS4 function might
promote tumorigenesis through its effect of prolonging
the duration of EGFR signaling (See Figure 4) [26].
Table 1 Frequency of salivary gland cancer by histologic type
Histologic Type Frequency of Occurrence Distribution
Mucoepidermoid carcinoma 34% Most common malignant parotid gland tumor, 40-50% of cases
Adenoid cystic carcinoma 22% Most frequent in palate and submaxillary gland
Adenocarcinoma 18% Accounts for 10% major and 33% of minor salivary gland malignant tumors
Malignant mixed tumor 13%
Acinic cell carcinoma 7% Accounts for 10% of malignant parotid gland tumors
Squamous cell carcinoma 4% Occurs in 5-10% of parotid and submaxillary gland malignant tumors
Other < 3%
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observed in a variety of cancers, including head and
neck, ovary, cervix, bladder, esophagus, stomach, brain,
breast, colon, and lung, and frequently confer an adverse
prognosis, but many cancers exhibited EGFR over-
expression in the absence of EGFR gene amplification
[27]. It is therefore postulated that the widespread phe-
nomenon of EGFR over-expression in human cancers
occurs, at least in part, as a consequence of common
pathological events, other than genomic changes, asso-
ciated with solid tumors.
Treatment
Although most parotid gland tumors grow slowly and
are noncancerous, they might continue to grow and can
eventually become cancerous. Surgery with the complete
removal the parotid gland (parotidectomy) and of the
tumor, including a cuff of histologically normal tissue
for adequate margins, is the mainstay treatment for par-
otid gland tumors. When there is direct extension of the
primary tumor into the neck, neck dissection is neces-
sary. The surgery can be complicated because several
important nerves are located in and around the gland
including the facial nerve (VII), which controls most
facial movements. Malignant deep lobe parotid gland
tumors require postoperative radiotherapy (RT) owing
to the limitations of surgical margins in their resection.
RT and chemotherapy/RT can also be considered as an
adjuvant setting for tumors of intermediate or high
grades. Studies [28,29] indicate that neutron-beam radia-
tion is more effective than conventional radiation
against malignant salivary gland disorders since it results
in a higher degree of tumor destruction with fewer toxic
effects to surrounding normal tissues. In treating
advanced, recurrent or incompletely resected adenoid
cystic carcinoma of the major and minor salivary glands,
Figure 3 Salivary gland malignant tumor pathology (200 ×).
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trol rate than photon therapy, and photon/neutron
mixed beam. Thus, it is a recommended treatment to
unresectable or inoperable cases. However, despite its
better local control, neutron-beam radiation does not
provide significant advantage in freedom from distant
failure over photons or mixed beam radiotherapy.
Furthermore, it does not have significant impact on sur-
vival, which is dominated by frequent distant metastases
among advanced cases.
Chemotherapy is usually for palliation or confined to
advanced disease. Responses have been reported after
single-agent chemotherapy and polychemotherapy.
Various agents, such as cisplatin, paclitaxel, cyclo-
phosphamide, doxorubicin, mitoxantrone, carboplatin,
and vinorelbine, and combinations of these have been
shown to be active for some malignant histologies [31].
Table 2 indicates the results of various palliative
mono- and poly-chemotherapy regimens for advanced
cases [32-38].
Although chemotherapy alone does not improve survi-
val rates, the integration of radiation and chemotherapy
has been shown to increase local control and represents
an improvement in the management of parotid gland
malignancies. Chemotherapy improves radiotherapy effi-
cacy through its radio-sensitizing ability, and at the
same time provides adjuvant systemic therapy against
distant micro-metastasis [39]. Some of the concurrent
chemotherapy and radiation therapy (chemoradiotherapy
[CRT]) regimens have become standard treatments for
locally advanced disease and high-risk pathology in defi-
nitive and postoperative setting, respectively.
Similar to those for other tumors, treatment selections
for parotid gland tumor is largely dependent upon the
extent and the pathology of the primary tumor as ascer-
tained by clinical examination, pathology, and interpre-
tation of appropriate radiographic images. According to
the National Comprehensive Cancer Network (NCCN)
2011 Clinical Practice Guidelines in Oncology: Head
and Neck Cancers [40], complete surgical excision is
required for parotid gland carcinomas T1 &T2 [41], or
clinically benign tumors, which are characterized by
being mobile, superficial, slow growing, painless, with
intact facial nerve (VII), and without neck nodes. No
additional treatment is envisaged if the excised tumor is
pathologically confirmed to be benign. However, if there
is tumor spillage or the tumor is pathologically proven
malignant, post-operation radiation therapy should be
considered, regardless of grade.
For parotid gland carcinomas T3 and above, further
surgical evaluation of local invasion or regional lymph
node metastasis has to be performed. In the case of car-
cinoma T4b, it is either no surgical resection would be
possible, or surgical resection is not recommended.
Definitive radiation therapy or radiation therapy with
systemic chemotherapy is recommended.
Among the clinical N0 (with no regional lymph node
metastasis) tumors, parotidectomy with complete exci-
sion of tumor with or without neck dissection for high-
grade and high-stage tumors is suggested, while the clin-
ical N+ (positive regional lymph node metastasis) require
parotidectomy and neck dissection. In the case of
incomplete excision with gross residual disease during
surgery, definitive radiation therapy or chemoradiation
therapy is recommended. Even for complete excision,
adjuvant radiation or chemoradiation therapy should
also be considered.
Future Developments
One of the reported side effects of radiation as treat-
ment for parotid gland cancer is hearing loss. Clinical
trials have been underway to determine whether
Figure 4 Diagram of tumorigenesis mechanism. Loss of VPS4
function promotes salivary gland tumorigenesis through its effect of
prolonging the duration of EGFR signaling.
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spares the cochlear is more effective than conventional
three-dimensional conformal radiation therapy (3D-
CRT) in reducing sensory-neural hearing loss in patients
who have radiotherapy treatment in the parotid gland
region. Data are still being collected before definitive
clinical guidelines can be put in place. Compared with
IMRT and 3D-CRT, the new radiation treatment
method of intensity-modulated proton therapy (IMPT)
allows for optimal dose distribution to the local target,
resulting in a dose reduction and improved sparing of
the organs at risk, while keeping similar target coverage
results [42]. Its potential benefit of lessening complica-
tions, such as salivary dysfunction, radionecrosis, or xer-
ostomia, requires further clinical validation.
Thanks to the advances in molecular biology and our
better understanding of the molecular mechanisms
underlying head and neck cancers, including parotid
gland cancer, new targeted therapeutics and novel agents
are also being developed for the systemic treatment to
them. The epidermal growth factor receptor (EGFR) is
one of the major targets under intensive investigation
s i n c ei th a sb e e nf o u n dt ob eo v e r e x p r e s s e di nh e a da n d
neck squamous cell carcinoma. This overexpression has
been linked to disease recurrence in which EGFR-depen-
dent signaling pathways are activated, leading to tumor
cell proliferation and anti-apoptosis. EGFR blockade has
hence been proposed to inhibit tumor growth. Cetuxi-
mab [43], an immunoglobulin-G1 antibody against
EGFR, and erlotinib, a small-molecule inhibitor of the
intracellular tyrosine kinase domain of EGFR, are among
the novel targeted therapeutic agents to result in
improved survival in patients with head and neck squa-
mous cell carcinoma. Furthermore, to target the vascular
endothelial growth factors (VEGF) and its receptors,
which are vital to the angiogenesis for tumor growths,
bevacizumab [44] and vanitinib, a monoclonal antibody
against VEGF and VEGF receptor-2 inhibitor, respec-
tively, are being clinically evaluated.
Conclusion
Although parotid gland cancer is relatively rare, it still
constitutes as a serious health hazard burdening our
population because of its poor prognosis. Twenty per-
cent of all patients will develop distant metastases
despite its large variety of histologic types. Distant
metastases usually correspond to a poor prognosis with
a median survival of 4 · 3-7 · 3 months [45]. Patients
with high-grade tumors have a higher chance of devel-
oping distant metastases than those with lower-grade
tumors. Nonetheless, with more being unraveled about
the disease, including its progression mechanisms at
molecular level and novel treatment regimens being
developed, we remain optimistic that locoregional con-
trol and overall patient survival will improve in not too
distant future.
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